Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update
08 août 2024 07h00 HE
|
Rapport Therapeutics, Inc.
Rapport Therapeutics announces financial results for Q2 2024 and provides a business update, including progress on its precision neuroscience pipeline
Avance Clinical Announces Senior Appointment to North American Operations
31 juil. 2024 02h45 HE
|
Avance Clinical
ADELAIDE, Australia and WAKE FOREST, N.C., July 31, 2024 (GLOBE NEWSWIRE) -- Avance Clinical, an award-winning, mid-sized full-service global Contract Research Organization (CRO) for biotech...
Kaerus Bioscience Announces Initiation of Phase 1 Clinical Trial for its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome
25 juil. 2024 05h00 HE
|
Kaerus Bioscience
LONDON, July 25, 2024 (GLOBE NEWSWIRE) -- Kaerus Bioscience Ltd. (www.kaerusbio.com), a clinical-stage biotechnology company focused on developing therapeutics for rare genetic syndromes of...
ConSynance Therapeutics Announces U.S. FDA Grants Rare Pediatric Disease Designation to CSTI-500, a Potential First-in-Class Therapy for Prader-Willi Syndrome
24 juil. 2024 10h00 HE
|
ConSynance Therapeutics
FDA awards ConSynance's CSTI-500 Rare Pediatric Disease Designation for innovative Prader-Willi Syndrome treatment.
Rapport Therapeutics Announces Pricing of Initial Public Offering
06 juin 2024 18h54 HE
|
Rapport Therapeutics, Inc.
BOSTON and SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational...
STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant) to treat cocaine use disorder
02 mai 2024 08h01 HE
|
STALICLA
Geneva, Switzerland, May 2, 2024 – STALICLA SA, a late-stage biotechnology company specializing in precision medicine for brain disorders, announces the First Patient First Visit (FPFV) for the...
New YPrime Report Highlights eCOA's Impact on CNS Trials
01 mai 2024 08h00 HE
|
Y-Prime, LLC
YPrime has released a new report, Insights into CNS Clinical Trials, which demonstrates to sponsors how eCOA can help streamline CNS research.
Alumis Announces First Participant Dosed in Phase 1 Clinical Trial of CNS Penetrant Allosteric TYK2 Inhibitor A-005
30 avr. 2024 08h00 HE
|
Alumis Inc
Alumis Inc. today announced that dosing has commenced in a Phase 1 clinical trial of A-005 in healthy participants.
FundaMental Pharma appoints Dr. Dirk Beher as Chief Executive Officer
11 avr. 2024 07h00 HE
|
Fundamental Pharma GmbH
PRESS RELEASE FundaMental Pharma appoints Dr. Dirk Beher as Chief Executive Officer Highly experienced biotech executive, with over a quarter of a century of CNS drug discovery experienceDr. Beher...
Alumis Presents Preclinical Data for Allosteric TYK2 Inhibitor A-005 at ACTRIMS
01 mars 2024 08h00 HE
|
Alumis Inc
– A-005 is a potential first-in-class, brain penetrant TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases – – Data support planned Phase 1 clinical trial on track to...